Warning letter
NeilMed Pharmaceuticals Inc.: warning letter of May 26, 2023
FDA warning letter 650263 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 650263 |
|---|---|
| Company | NeilMed Pharmaceuticals Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | May 26, 2023 |
| Posted date | Jul 11, 2023 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| CFR sections cited | 211.34, 211.67(a), 211.84(d)(1) |
| Inspection city | Santa Rosa |
| Inspection ZIP | 95403 |
| Inspection start date | Nov 28, 2022 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: